SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.15+2.5%Jan 5 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mr. E2u who wrote (10143)1/26/2004 2:45:58 PM
From: Biomaven  Read Replies (1) of 52153
 
I looked briefly at GMED a while back. They believe that ARBs (angiotensin II receptor blockers) are a cure for everything. Even if they are correct (and I believe their claims are considerably exaggerated, although perhaps there is an interesting idea there, particularly for the treatment of SARS) there's the minor detail that all the approved ARBs (there are about half-a-dozen of them in the US) are patented drugs that belong to other companies. So it's hard to see how they would make any money on them.

There's a reason most pink sheet stocks are on the pink sheets.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News